Australia Point-of-care Molecular Diagnostics Market Size & Outlook
Related Markets
Australia point-of-care molecular diagnostics market highlights
- The Australia point-of-care molecular diagnostics market generated a revenue of USD 165.8 million in 2024 and is expected to reach USD 304.6 million by 2033.
- The Australia market is expected to grow at a CAGR of 7% from 2025 to 2033.
- In terms of segment, infectious diseases was the largest revenue generating application in 2024.
- Oncology is the most lucrative application segment registering the fastest growth during the forecast period.
Point-of-care molecular diagnostics market data book summary
| Market revenue in 2024 | USD 165.8 million |
| Market revenue in 2033 | USD 304.6 million |
| Growth rate | 7% (CAGR from 2025 to 2033) |
| Largest segment | Infectious diseases |
| Fastest growing segment | Oncology |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Oncology, Prenatal Testing, Endocrinology, Other Applications, Hematology, Infectious Diseases |
| Key market players worldwide | Roche, Abbott Laboratories, Qiagen NV, Bayer AG, Nova Biomedical, Danaher Corp, Nipro Corp, Bio-Rad Laboratories Inc, Agilent Technologies Inc, BioMerieux SA, OraSure Technologies Inc, Abaxis |
Other key industry trends
- In terms of revenue, Australia accounted for 2.0% of the global point-of-care molecular diagnostics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China point-of-care molecular diagnostics market is projected to lead the regional market in terms of revenue in 2033.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 618.5 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Point-of-Care Molecular Diagnostics Market Scope
Point-of-Care Molecular Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Abaxis | View profile | 5001-10000 | Union City, California, United States, North America | http://abaxis.com |
| OraSure Technologies Inc | View profile | 638 | 220 East First Street, Bethlehem, PA, United States, 18015 | https://www.orasure.com |
| Roche | View profile | 10001+ | Basel, Basel-Stadt, Switzerland, Europe | http://www.roche.com |
| Nipro Corp | View profile | 39713 | 3-9-3 Honjo-Nishi Kita-ku, Osaka, Japan, 531-8510 | http://www.nipro.co.jp |
| Bayer AG | View profile | 99723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | https://www.bayer.com |
| Nova Biomedical | View profile | 501-1000 | Waltham, Massachusetts, United States, North America | http://www.novabio.us |
| Qiagen NV | View profile | 5900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | https://www.qiagen.com |
| Bio-Rad Laboratories Inc | View profile | 8030 | 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 | https://www.bio-rad.com |
| Agilent Technologies Inc | View profile | 17700 | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 | https://www.agilent.com |
| Danaher Corp | View profile | 63000 | 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 | https://www.danaher.com |
| BioMerieux SA | View profile | 13982 | Marcy l’Etoile, Lyon, France, 69280 | http://www.biomerieux.com |
| Abbott Laboratories | View profile | 114000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | https://www.abbottinvestor.com |
Australia point-of-care molecular diagnostics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to point-of-care molecular diagnostics market will help companies and investors design strategic landscapes.
Infectious diseases was the largest segment with a revenue share of 50.18% in 2024. Horizon Databook has segmented the Australia point-of-care molecular diagnostics market based on oncology, prenatal testing, endocrinology, other applications, hematology, infectious diseases covering the revenue growth of each sub-segment from 2021 to 2033.
Several developments in the country by key players have contributed to the market growth. For instance, in March 2023, Microbix Biosystems, Inc. announced that it supports the Australian POC testing program for STIs in remote communities across Australia. Similarly, in 2020, ZiP Diagnostics received funding of USD 600,000 as part of the BioMedTech Horizons (BMTH) program’s Round 3, facilitated by MTPConnect.
The funds obtained through this grant were used to develop and commercialize innovative POC test products targeting different diseases, including STIs and SARS-CoV2. Furthermore, as per WHO, the country registered more than 5.8 million confirmed cases of COVID-19 and over 7,200 deaths between January 2020 and May 2022.
The impact of the pandemic was relatively low compared to other nations in Asia Pacific. This low number can be attributed to the largescale testing of individuals across the country. New South Wales had the highest testing rate for COVID19, with over 342,000 tests per 100,000 individuals.
Reasons to subscribe to Australia point-of-care molecular diagnostics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia point-of-care molecular diagnostics market databook
-
Our clientele includes a mix of point-of-care molecular diagnostics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia point-of-care molecular diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Australia point-of-care molecular diagnostics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Australia Application - Point-of-care Molecular Diagnostics Market size, 2024 - 2033 (US$M)
Australia Point-of-Care Molecular Diagnostics Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
